Uncategorized
- How do you know you have viable tissue?
- How do you know that you have immune cell infiltration?
- How do you accommodate for the different types of cytokine responses and how they are confounded?
- How do you know you maintain the TME?
- Do you have the ability to test every ICI directly on the tissue, even within an MOA?
- Is this fast enough for urgent treatment decisions?
- Does the cloud-based web portal have security features or integrations for sending/receiving data around results?
- How can you trust a biosimilar? (research-grade biosimilar)
- How are you different than Tempus/BostonGene?
- How can this work across different treatments?
- Why does this require a Core Needle Biopsy? There is so little tissue and high heterogeneity
- vs IPS Tempus?
- The platform seems expensive to implement; is it cost-effective compared to traditional omics-based diagnostics, especially for smaller clinics or labs?
- Where's the robust trial data showing improved patient outcomes?
- How do you know you don't have false negatives?
- Can CTLA-4 work outside of draining lymph nodes?
- How is drug dose for the ex vivo sample determined?
- What is your sensitivity/specificity?
- Requiring fresh tumor biopsies adds complexity. How do we ensure sample viability during transport, and what if delays occur in getting results within the promised 72 hours?
- How can you not test for chemo or TKI or other regimen components?
- Is this test/platform FDA approved?
- Will insurance cover this as a diagnostic tool? What about the extra biopsy or two?
- How can you normalize for differences in samples? How can you not have replicates?
- Isn't it difficult for an IR to not use formalin?
- How do you deal with biopsies while patients are on treatment?